Business Context and Reporting Period
Xencor, Inc. filed a Form 8-K Current Report on February 4, 2019, regarding the entry into a Material Definitive Agreement. The company, incorporated in Delaware, is based in Monrovia, California.
Key Financial Metrics and Agreement Terms
This filing details a Collaboration and License Agreement with Genentech, Inc. and Hoffmann-LaRoche Ltd. Key financial terms include:
- Upfront Payment: $120 million.
- Clinical Milestones: Up to $160 million per Collaboration Product upon advancement to Phase 3 clinical trials.
- Research Milestones: $20 million per new Collaboration Product identified and advancing to Phase 1 clinical trials.
- Profit/Loss Sharing: Xencor is eligible for a 45% share of net profits and shares net losses at the same rate.
- Cost Sharing: Development and commercialization costs are shared at a 45% rate; Genentech bears launch costs entirely.
- Commercialization Rights: Genentech holds worldwide exclusive rights, with Xencor retaining a co-promotion option in the United States.
Material Changes and Outlook
The agreement represents a significant strategic partnership focused on developing and commercializing novel IL-15 cytokine therapeutics, specifically XmAb24306, for cancer immunotherapy. The collaboration includes a two-year joint research period to discover additional candidates. Closing is expected in the first half of 2019, subject to customary conditions including Hart-Scott-Rodino Antitrust clearance.
Risks and Contingencies
- Closing Conditions: The agreement is contingent upon regulatory clearance and other customary closing conditions.
- Termination Rights: Genentech may terminate the agreement entirely or on a product basis with written notice. Xencor may terminate on a product basis if Genentech fails to meet minimum spending requirements on research, development, or commercialization.
- Confidentiality: Certain portions of the agreement are subject to a request for confidential treatment and will be omitted from the public filing of the Form 10-Q.
Investor Verification Checklist
- Verify the actual closing date of the agreement and receipt of the $120 million upfront payment.
- Monitor the progress of XmAb24306 and other Collaboration Products toward Phase 3 clinical trials to assess milestone eligibility.
- Review the upcoming Form 10-Q for the fiscal quarter ending March 31, 2019, for the full text of the agreement and any confidential treatment requests.
- Track Genentech's spending on research and commercialization to ensure compliance with minimum thresholds required to prevent termination by Xencor.